JW HOLDINGS CORPORATION is a Korea-based holding company mainly engaged in the subsidiary management and pharmaceutical distribution businesses. The Company's products are imipenem, itraconazole, nutrients fluids, general fluids and others. Its subsidiaries include W PHARMACEUTICAL CORPORATION, engaged in the manufacture of pharmaceuticals, such as diabetic agents, urology agents, nephrology agents and others; JW SHINYAK CORPORATION, engaged in the manufacture of pharmaceuticals, such as antibiotics, skin drugs, obesity drugs, allergy drugs and others, and JW Medical Corporation, engaged in the manufacture of medical equipment, such as magnetic resonance imaging (MRI) equipment, computed tomography (CT) equipment and others, among others. On November 9, 2011, the Company established a wholly owned subsidiary, mainly engaged in the real estate investment (REIT) business. On January 19, 2011 the Company changed its name from CHOONGWAE HOLDINGS.CO., LTD. to JW HOLDINGS CORPORATION.
(Source: ARS)